# BIOPTIC

> BIOPTIC, operated by Optic, Inc., combines specialized AI agents, pharma data and expert review to research drug assets, competitors and launch opportunities for pharmaceutical teams and life sciences investors. Its commercial research services grew out of molecular-screening work using its B1 model.

- **Founded:** 2022
- **Headquarters:** San Francisco, United States
- **Founders:** Andrey Doronichev (Co-founder and CEO), Vlad Vinogradov (Co-founder and VP, AI), Roman Doronin (Co-founder and VP, Engineering)
- **Products:** Asset scouting and in-licensing, Competitive intelligence, Due diligence, Launch planning, Custom research
- **Notable:** AAAI 2026 paper reports 83% competitor-discovery recall on its constructed benchmark and an investment-fund case study reducing competitive-analysis turnaround from 2.5 days to approximately 3 hours., Company reports an AAAI 2026 Deployed Application Award., B1 molecular search preprint released June 2024; JCIM LRRK2 publication followed in 2025.

## Products & services

- **Asset scouting and in-licensing** — Find and rank drug assets against agreed scientific and commercial criteria, including Chinese-language records; advertised turnaround 24-48 hours.
- **Competitive intelligence** — Map competing assets, evidence and milestones, with optional scheduled monitoring; initial reports typically 48-72 hours.
- **Due diligence** — Company and asset assessments covering clinical evidence, patents, competitors, deal comparables and open questions; typically 24-48 hours.
- **Launch planning** — Positioning research, patient journeys, evidence gaps, market comparisons and forecast inputs; typically 72-96 hours.
- **Custom research** — Research projects with scope, deliverables, review and timing agreed with the client.
- **BIOPTIC platform** — Parallel research agents, connected pharma evidence, source passages and daily, weekly or monthly monitoring in a shared workspace.
- **B1** — Ligand-based molecular search model; public preprint introduced in June 2024, followed by published discovery applications.
- **B2** — Sequence-based compound model described as in evaluation with academic partners.
- **B3** — ADMET prediction model described on the research site.

## Achievements

- AAAI 2026 paper reports 83% competitor-discovery recall on its constructed benchmark and an investment-fund case study reducing competitive-analysis turnaround from 2.5 days to approximately 3 hours.
- Company reports an AAAI 2026 Deployed Application Award.
- B1 molecular search preprint released June 2024; JCIM LRRK2 publication followed in 2025.
- Stanford-led Friedreich’s ataxia study used B1 screening, followed by compound synthesis and testing in patient-derived neurons.
- Hunt Globally preprint reports 79.7% F1 on a company-authored multilingual asset-scouting benchmark; submitted February 2026, revised May 2026.

## Latest updates

- **2026-08** — Founder told Oninvest the company was raising another round; no completed new round was established in that report.
- **2026-06** — BIOPTIC announced the Stanford-led Cell Chemical Biology study using B1 for Friedreich’s ataxia research.
- **2026-05** — Hunt Globally asset-scouting preprint revised to version 5.
- **2026-03** — AAAI competitive-landscape paper published March 14, 2026.
- **2026-01** — BIOPTIC reported its AAAI Deployed Application Award.

## Links

- Website: https://www.bioptic.io/
- LinkedIn: https://www.linkedin.com/company/optic-inc
- Twitter/X: https://x.com/BiopticIO
- GitHub: https://github.com/optic-inc

---

Profile page: https://yespress.io/bioptic
Published by YesPress — https://yespress.io
Last updated: 2026-10-25